These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 77316)

  • 1. Myoclonic attacks induced by L-dopa and bromocryptin in Parkinson patients: a sleep EEG study.
    Vardi J; Glaubman H; Rabey JM; Streifler M
    J Neurol; 1978 Apr; 218(1):35-42. PubMed ID: 77316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L-dopa induced "serotonin syndrome" in a parkinsonian patient on bromocriptine.
    Sandyk R
    J Clin Psychopharmacol; 1986 Jun; 6(3):194-5. PubMed ID: 3711372
    [No Abstract]   [Full Text] [Related]  

  • 3. EEG sleep patterns in Parkinsonian patients treated with bromocryptine and L-dopa: a comparative study.
    Vardi J; Glaubman H; Rabey J; Streifler M
    J Neural Transm; 1979; 45(4):307-16. PubMed ID: 490153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Myoclonic attacks induced by bromocriptine in Parkinsonian patients].
    Glaubman H; Rabey I; Vardi J
    Harefuah; 1979 Jan; 96(2):90-2. PubMed ID: 478382
    [No Abstract]   [Full Text] [Related]  

  • 5. Hypersexuality--a complication of dopaminergic therapy in Parkinson's disease.
    Vogel HP; Schiffter R
    Pharmacopsychiatria; 1983 Jul; 16(4):107-10. PubMed ID: 6685318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa.
    Brunt ER; Brooks DJ; Korczyn AD; Montastruc JL; Stocchi F;
    J Neural Transm (Vienna); 2002 Apr; 109(4):489-502. PubMed ID: 11956968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bromocriptine in the treatment of Parkinson's disease: a double-blind study against L-dopa/carbidopa.
    Gawel M; Riopelle R; Libman I; Bouchard S
    Adv Neurol; 1987; 45():535-8. PubMed ID: 3548263
    [No Abstract]   [Full Text] [Related]  

  • 8. Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued.
    Przuntek H; Welzel D; Blümner E; Danielczyk W; Letzel H; Kaiser HJ; Kraus PH; Riederer P; Schwarzmann D; Wolf H
    Eur J Clin Pharmacol; 1992; 43(4):357-63. PubMed ID: 1451713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
    Libman I; Gawel MJ; Riopelle RJ; Bouchard S
    Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EEG sleep study in parkinsonian patients under bromocryptine treatment.
    Rabey J; Vardi J; Glaubman H; Streifler M
    Eur Neurol; 1978; 17(6):345-50. PubMed ID: 744200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bromocriptine in Parkinsonian syndromes. Results obtained in a group of patients treated for 8 months].
    Quattrini A; Paggi A; Del Pesce M; Di Bella P
    Riv Patol Nerv Ment; 1978; 99(3):150-63. PubMed ID: 752907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levodopa-induced myoclonus.
    Klawans HL; Goetz C; Bergen D
    Arch Neurol; 1975 May; 32(5):330-4. PubMed ID: 1079721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bromocriptine alone or associated with L-dopa plus benserazide in Parkinson's disease.
    Caraceni TA; Celano I; Parati E; Girotti F
    J Neurol Neurosurg Psychiatry; 1977 Dec; 40(12):1142-6. PubMed ID: 591982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levodopa compared with bromocriptine in the treatment of Parkinson's disease.
    Godwin-Austen RB
    Adv Biochem Psychopharmacol; 1980; 23():261-5. PubMed ID: 7395616
    [No Abstract]   [Full Text] [Related]  

  • 15. Plasma dopamine beta hydroxylase (D.B.H.) activity in Parkinsonian patients under L-dopa, and 2-bromo-alpha-ergocriptine loading.
    Vardi J; Flechter S; Oberman Z; Allelov M; Rabey JM; Hertzberg M; Streifler M
    J Neural Transm; 1979; 46(1):71-8. PubMed ID: 501350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis.
    Nausieda PA; Weiner WJ; Kaplan LR; Weber S; Klawans HL
    Clin Neuropharmacol; 1982; 5(2):183-94. PubMed ID: 7139632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bromocriptine combined with levodopa in Parkinson's disease.
    Gauthier G; Martins da Silva A
    Eur Neurol; 1982; 21(4):217-26. PubMed ID: 7117308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of bromocriptine and levodopa in Parkinson's disease.
    Duvoisin RC; Mendoza MM; Yahr MD
    Adv Biochem Psychopharmacol; 1980; 23():271-5. PubMed ID: 7395618
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of Parkinson's disease with dopamine agonists: a review.
    Lieberman A; Neophytides A; Kupersmith M; Casson I; Durso R; Foo SH; Khayali M; Tartaro T; Goldstein M
    Am J Med Sci; 1979; 278(1):65-76. PubMed ID: 39452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Secondary effects of prolonged levodopa therapy in Parkinson's disease].
    Peiró Grasa A; Grau-Veciana JM
    Med Clin (Barc); 1985 Jun; 85(3):88-91. PubMed ID: 4021630
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.